← k3vl4r
Log inGet started →

NNVC (NanoViricides Inc) Price Forecast

AI-generated price forecast for NanoViricides Inc (NNVC) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of September 2026: K3vl4r's AI model currently reads NNVC as 1/1 bullish across its horizons (1 of 1 timeframes pointing up), with a last price of 1.11. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

1.11

AI outlook

1/1 bullish

Timeframes up

1 / 1

Share𝕏PostTelegram

NNVC forecast by horizon

HorizonDirectionProjected move (end of horizon)Bullish prob.
1-hour———
4-hour~3 weeks out———
Daily~4 months out▲ Up+7.29%—
Weekly~1.8 years out———

Latest NNVC news

From the market-news feed the forecasts are read against.

  • NanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database · Benzinga · Sep 8
  • While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles · Yahoo · Aug 31
  • NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric Disease Designation · Benzinga · Aug 31
  • NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congo · Benzinga · Aug 18
  • NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola · Benzinga · Aug 10

🔒

See the full NNVC forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

NNVC forecast — frequently asked

Will NNVC go up?

K3vl4r's AI model currently reads NNVC as 1/1 bullish — 1 of 1 forecast horizons point up, so the overall read is leaning to the upside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the NNVC price prediction for 2026?

K3vl4r's model projects NNVC toward $1.12 over the next ~4 months, a +0.1% move from $1.12. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

STOKTBPHCTXRTWSTNBPLFSTAVTXRGNXQNTMPRAXELVNARVNACRVGNTA

Will NNVC reach…?

Will NNVC reach $2.00?Will NNVC reach $3.00?Will NNVC reach $5.00?

Or see the full NNVC price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare NNVC

NNVC vs STOKNNVC vs TBPHNNVC vs CTXRNNVC vs TWSTNNVC vs NBPNNVC vs LFST

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rTop PicksTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.